Carfilzomib for relapsed and refractory multiple myeloma

Overview of attention for article published in Cancer Management and Research, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 53 Dimensions

Readers on

mendeley: 98 Mendeley

Summary X Patents Dimensions citations

So far, Dimensions has found 53 publications that cite this research output.

53

The most recent citing publications are shown below. View all 53 publications that cite this research output on Dimensions.

Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma

Article in Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (January 2024)

Exosomal miR-182 derived from bone marrow mesenchymal stem cells drives carfilzomib resistance of multiple myeloma cells by targeting SOX6

Article in Journal of Orthopaedic Surgery and Research (December 2023)

Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3/NF-κB and PI3K/Akt/GSK-3β/MAPK axes

Article in Life Sciences (November 2023)